Anthropometric indices of fat distribution and cardiometabolic risk in Parkinson's disease

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 3, 2013, Pages 264-271

  Cereda, E ^a,b   Cassani, E ^b   Barichella, M ^b   Caccialanza, R ^a   Pezzoli, G ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b PARKINSON INSTITUTE   (Italy)

Author keywords

Cardiometabolic risk; Parkinson's disease; Waist circumference (WC); Waist hip ratio (WHR); Waist to height ratio (WtHR)

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADIPOSE TISSUE; AGED; ANTHROPOMETRY; ARTICLE; BLOOD; BODY FAT DISTRIBUTION; BODY MASS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; NUTRITIONAL ASSESSMENT; OBESITY; PARKINSON DISEASE; PREVALENCE; RISK FACTOR;

ADIPOSE TISSUE; ADIPOSITY; AGED; ANTHROPOMETRY; BLOOD GLUCOSE; BODY FAT DISTRIBUTION; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NUTRITION ASSESSMENT; OBESITY; PARKINSON DISEASE; PREVALENCE; RISK FACTORS; TRIGLYCERIDES;

EID: 84875242433     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2011.04.004     Document Type: Article

References (43)

1. Pischon T., Boeing H., Hoffmann K., Bergmann M., Schulze M.B., Overvad K., et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008, 359:2105-2120.
2. Whitlock G., Lewington S., Sherliker P., Clarke R., Emberson J., Halsey J., et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009, 373:1083-1096. Prospective Studies Collaboration.
3. Calza S., Decarli A., Ferraroni M. Obesity and prevalence of chronic diseases in the 1999-2000 Italian national health survey. BMC Public Health 2008, 8:140.
4. Strategies in reducing cardiometabolic risk. Am J Med 2009, 122(4 Suppl. 1):S1-S52. The Obesity Epidemic.
5. Montague C.T., O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000, 49:883-888.
6. Wajchenberg B.L. Subcutaneous and visceral adipose tissue: their Relation to the metabolic syndrome. Endocr Rev 2000, 21:697-738.
7. Ritchie S.A., Connell J.M.C. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 2007, 17:319-326.
8. Janssen I., Katzmarzyk P.T., Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 2004, 79:379-384.
9. Schneider H.J., Glaesmer H., Klotsche J., Böhler S., Lehnert H., Zeiher A.M., et al. DETECT Study Group. Accuracy of anthropometric indicators of obesity to predict cardiovascular risk. J Clin Endocrinol Metab 2007, 92:589-594.
10. de Koning L., Merchant A.T., Pogue J., Anand S.S. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J 2007, 28:850-856.
11. Huxley R., Mendis S., Zheleznyakov E., Reddy S., Chan J. Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk-a review of the literature. Eur J Clin Nutr 2010, 64:16-22.
12. Schneider H.J., Friedrich N., Klotsche J., Pieper L., Nauck M., John U., et al. The predictive value of different measures of obesity for incident cardiovascular events and mortality. J Clin Endocrinol Metab 2010, 95:1777-1785.
13. Expert panel on detection. Evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCPE) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001; 2001: 2486e97.
14. Barichella M., Marczewska A., Vairo A., Canesi M., Pezzoli G. Is underweightness still a major problem in Parkinson's disease patients?. Eur J Clin Nutr 2003, 57:543-547.
15. Barichella M., Cereda E., Pezzoli G. Major nutritional issues in the management of Parkinson's disease. Mov Disord 2009, 24:1881-1892.
16. Markus H.S., Tomkins A.M., Stern G.M. Increased prevalence of undernutrition in Parkinson's disease and its relationship to clinical disease parameters. J Neural Transm Park Dis Dement Sect 1993, 5:117-125.
17. Beyer P.L., Palarino M.Y., Michalek D., Busenbark K., Koller W.C. Weight change and body composition in patients with Parkinson's disease. J Am Diet Assoc 1995, 95:979-983.
18. Montaurier C., Morio B., Bannier S., Derost P., Arnaud P., Brandolini-Bunlon M., et al. Mechanisms of body weight gain in patients with Parkinson's disease after subthalamic stimulation. Brain 2007, 130:1808-1818.
19. Scigliano G., Musicco M., Soliveri P., Piccolo I., Ronchetti G., Girotti F. Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 2006, 37:1184-1188.
20. Scigliano G., Ronchetti G., Girotti F., Musicco M. Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease. Parkinsonism Relat Disord 2009, 15:138-143.
21. Fall P.A., Saleh A., Fredrickson M., Olsson J.E., Granérus A.K. Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up. Mov Disord 2003, 18:1312-1316.
22. Beyer M.K., Herlofson K., Arsland D., Larsen J.P. Causes of death in a community-based study of Parkinson's disease. Acta Neurol Scand 2001, 103:7-11.
23. Cereda E., Sansone V., Meola G., Malavazos A.E. Increased visceral adipose tissue rather than BMI as a risk factor for dementia. Age Ageing 2007, 36:488-491.
24. Mutez E., Duhamel A., Defebvre L., Bordet R., Destée A., Kreisler A. Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease. Pharm Res 2009, 60:41-45.
25. Hughes A.J., Ben-Shlomo Y., Daniel S.E., Lees A.J. What features improves the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 2001, 57(Suppl 3):S34-S38.
26. Cereda E., Bertoli S., Battezzati A. Height prediction formula for middle-aged (30-55y) Caucasians. Nutrition 2010, 26:1075-1081.
27. Physical status: the use and interpretation of anthropometry. Report of a WHO expert committee. World Health Organ Tech Rep Ser 1995, 854:1-452. World Health Organization.
28. Kyle U.G., Bosaeus I., De Lorenzo A.D., Deurenberg P., Elia M., Gómez J.M., et al. Composition of the ESPEN working group. Bioelectrical impedance analysis-part I: review of principles and methods. Clin Nutr 2004, 23:1226-1243.
29. Mappe, Popolazione, Statistiche Demografiche dell'Istituto Nazionale di Statistica [accessed September 01.09.10], at http://demo.istat.it/.
30. Miccoli R., Bianchi C., Odoguardi L., Penno G., Caricato F., Giovannitti M.G., et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis 2005, 15:250-254.
31. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821-1830.
32. Wakabayashi K., Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997, 38(Suppl 2):2-7.
33. Carmichael S.W., Wilson R.J., Brimijoin W.S., Melton L.J., Okazaki H., Yaksh T.L., et al. Decreased catecholamines in the adrenal medulla of patients with Parkinsonism. N Engl J Med 1988, 28:254.
34. Whitsett T.L., Halushka P.V., Goldberg L.I. Attenuation of postganglionic sympathetic nerve activity by L-dopa. Circ Res 1970, 27(561):e70.
35. Lee J.M., Park K.W., Seo W.K., Park M.H., Han C., Jo I., et al. Carotid intima-media thickness in Parkinson's disease. Mov Disord 2007, 22:2446-2449.
36. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 2000, 43:533-549.
37. Leblanc H., Lachelin G.C., Abu-Fadil S., Yen S.S. The effect of dopamine infusion on insulin and glucagon secretion in man. J Clin Endocrinol Metab 1977, 44(196):e8.
38. Sirtori C.R., Bolme P., Azarnoff D.L. Metabolic responses to acute and chronic L-dopa administration in patients with Parkinsonism. N Engl J Med 1972, 287:729-733.
39. Møller N., Jørgensen J.O. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009, 30:152-177.
40. Rankinen T., Kim S.Y., Pérusse L., Després J.P., Bouchard C. The prediction of abdominal visceral fat level from body composition and anthropometry: ROC analysis. Int J Obes Relat Metab Disord 1999, 23:801-809.
41. Cereda E., Barichella M., Pezzoli G. Controlled-protein dietary regimens for Parkinson's disease. Nutr Neurosci 2010, 13:29-32.
42. Cereda E., Barichella M., Pedrolli C., Pezzoli G. Low-protein and protein-redistribution diets for Parkinson's disease patients with motor fluctuations: a systematic review. Mov Disord 2010, 25:2021-2034.
43. Marczewska A., De Notaris R., Sieri S., Barichella M., Fusconi E., Pezzoli G. Protein intake in Parkinsonian patients using the EPIC food frequency questionnaire. Mov Disord 2006, 21:1229-1231.